{"id":"ad-223c","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, AD-223C prevents the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.","oneSentence":"AD-223C is a small molecule that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:28.052Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT06052748","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of AD-223","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2024-02-15","conditions":"Hypertension,Essential","enrollment":502}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AD-223C","genericName":"AD-223C","companyName":"Addpharma Inc.","companyId":"addpharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AD-223C is a small molecule that targets the PD-1 receptor. Used for Metastatic non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}